A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QMF149 in Japanese Patients With Asthma
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Indacaterol/mometasone (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
- 23 Aug 2019 Status changed from active, no longer recruiting to completed.
- 25 Sep 2018 Status changed from recruiting to active, no longer recruiting.